Relative inhibitory activities of newly developed diazabicyclooctanes, boronic acid derivatives, and penicillin-based sulfone β-lactamase inhibitors against broad-spectrum AmpC β-lactamases.

enmetazobactam (AAI101) - Allecra

taniborbactam (VNRX-5133) - VenatoRx

relebactam (MK-7655) - Merck (MSD)

nacubactam (RG6080) - Roche, Meiji Seika

OMNIvance (xeruborbactam) - Shionogi

http://www.ncbi.nlm.nih.gov/pubmed/39365068

Christophe Le Terrier; Laurent Poirel; Mustafa Sadek; Patrice Nordmann; Patrik Mlynarcik

Oct 4, 2024